Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p
NCT ID: NCT05850117
Last Updated: 2023-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
240 participants
INTERVENTIONAL
2020-02-10
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To investigate the drug resistance of Helicobacter pylori and the host genotypes of CYP2C19 and IL-1B-511 on the sterilizing effect of three second-line Helicobacter pylori.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection
NCT02978157
Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection
NCT03779087
Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses
NCT05431075
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
NCT00669955
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection
NCT02175927
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tetracycline combined with levofloxacin quadruple therapy
esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day+ tetracycline 500mg four times a day+ levofloxacin 500mg once a day
esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin
Tetracycline combined with levofloxacin quadruple therapy
standard tincture quadruple therapy
esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day
\+ tetracycline 500mg four times a day + metronidazole 250mg four times a day
esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole
standard tincture quadruple therapy
amoxicillin combined with levofloxacin quadruple therapy
esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day+ amoxicillin 500mg four times a day+ levofloxacin 500mg once a day
esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin
amoxicillin combined with levofloxacin quadruple therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin
Tetracycline combined with levofloxacin quadruple therapy
esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole
standard tincture quadruple therapy
esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin
amoxicillin combined with levofloxacin quadruple therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. subject was failure for the first line therapy of Helicobacter pylori
Exclusion Criteria
2. Those who have had a stomach surgery
3. Those who have antibiotics within four weeks of treatment
4. Those who have severe cirrhosis, uremia or malignancy
5. Those who are a pregnant woman or a woman who breastfeeds
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaohsiung Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
DENG-CHYANG WU
clinical professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Medical University Hospital
Kaohsiung City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KMUHIRB-F(I)-20190136
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.